NEW YORK (GenomeWeb) – Leerink today upgraded shares of Bruker to an Outperform rating, noting that the company's operational improvements have begun to show results and that its competitive position in the NMR market has improved significantly with Agilent's exit from this space last year.

Analyst Dan Leonard upgraded the company's stock from a previous Market Perform rating and increased the bank's price target on Bruker's shares to $24 from $21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.